Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 21
Filter
1.
Int J Legal Med ; 133(6): 1869-1877, 2019 Nov.
Article in English | MEDLINE | ID: mdl-30911839

ABSTRACT

PURPOSE: Forensic investigations could benefit from non-invasive in situ characterization of bullets. Therefore, the use of CT imaging was explored for the analysis of bullet geometry and composition. Bullet visualization with CT is challenging as the metal constituents suffer from excessive X-ray attenuation due to their high atomic number, density, and geometry. METHODS: A metal reference phantom was developed containing small discs of various common metals (aluminum, iron, stainless steel, copper, brass, tungsten, and lead). CT images were acquired with 70-150 kVp and 200-400 mAs and were reconstructed using an extended Hounsfield unit (HU) scale (- 10,240 to + 30,710). For each material, the mean CT number (HU) was measured to construct a metal database. Different bullets (n = 11) were scanned in a soft tissue-mimicking phantom. Bullet size and shape were measured, and composition was evaluated by comparison with the metal database. Also, the effect of bullet orientation within the CT scanner was evaluated. RESULTS: In the reference phantom, metals were classified into three groups according to their atomic number (Z): low (Z ≤ 13; HU < 3000), medium (Z = 25-30; HU = 13,000-20,000), and high (Z ≥ 74; HU > 30,000). External bullet contours could be accurately delineated. Internal interfaces between jacket and core could not be identified. Cross-sectional spatial profile plots of the CT number along bullets' short axis revealed beam hardening and photon starvation effects that depended on bullet size, shape, and orientation within the CT scanner. Therefore, the CT numbers of bullets were unreliable and could not be used for material characterization by comparison with the reference phantom. CONCLUSION: CT-based characterization of bullets was feasible in terms of size and shape but not composition.


Subject(s)
Forensic Ballistics , Metals , Phantoms, Imaging , Tomography, X-Ray Computed , Firearms , Humans
2.
Physiol Res ; 67(Suppl 4): S655-S664, 2018 12 31.
Article in English | MEDLINE | ID: mdl-30607972

ABSTRACT

Cardiovascular pathologies are frequently associated with anxiety and other behavioral disturbances. Ivabradine, an inhibitor of the hyperpolarization-activated cyclic nucleotide-gated channels in the sinoatrial node, decreases heart rate and provides cardiovascular protection. Although ivabradine is increasingly used in cardiovascular medicine, the data on its behavioral effects are lacking. The aim of this work was to show ivabradine's potential effect on behavior in healthy and hypertensive rats. After a four-week treatment period, systolic blood pressure was increased in the N(G)-nitro-L-arginine methyl ester (L-NAME)-group and ivabradine significantly reduced it. Furthermore, it reduced the heart rate in both the control and L-NAME-group. In the control group, ivabradine enhanced the time spent in and transition to the open arms of the elevated plus maze test (EPM). In the L-NAME-group, ivabradine does not show a significant effect on the time spent in the EPM open arms and the number of transitions into them. Furthermore, ivabradine has no impact on cognitive function in both control and L-NAME groups. We conclude that ivabradine showed no undesirable effects on anxiety, locomotion or learning; in fact, some of these parameters were even improved. For the first time it has been shown that ivabradine is a safe cardiovascular drug regarding its effect on psycho-behavioral manifestations.


Subject(s)
Anxiety , Hypertension/chemically induced , Hypertension/drug therapy , Ivabradine/therapeutic use , Memory/drug effects , NG-Nitroarginine Methyl Ester/toxicity , Animals , Anxiety/physiopathology , Blood Pressure/drug effects , Blood Pressure/physiology , Enzyme Inhibitors/pharmacology , Enzyme Inhibitors/therapeutic use , Heart Rate/drug effects , Heart Rate/physiology , Hypertension/physiopathology , Ivabradine/pharmacology , Male , Memory/physiology , Rats , Rats, Wistar
3.
J Physiol Pharmacol ; 67(6): 895-902, 2016 Dec.
Article in English | MEDLINE | ID: mdl-28195070

ABSTRACT

Cardiovascular diseases including hypertension are often associated with behavioural alterations. The aim of this study was to show, whether ivabradine, the blocker of If-channel in sinoatrial node, is able to modify the behaviour of rats in L-nitro-arginine methyl ester (L-NAME)-induced hypertension and to compare the effect of ivabradine with captopril and melatonin. 12-week-old male Wistar rats were divided into the following groups: controls, ivabradine (10 mg/kg/24 h), L-NAME (40 mg/kg/24 h), L-NAME + ivabradine, L-NAME + captopril (100 mg/kg/24 h), L-NAME + melatonin (10 mg/kg/24 h). Systolic blood pressure (SBP) and heart rate (HR) were measured by tail-cuff method once a week. The behaviour of rats was investigated during 23-hours in the phenotyper after four weeks of the treatment. Chronic administration of L-NAME induced hypertension without a change in HR. All tested substances partly prevented the increase of SBP, while ivabradine and melatonin also reduced HR. Ivabradine, captopril and melatonin reduced daily food intake, slightly decreased daily water intake and attenuated body weight gain. In L-NAME group, locomotor activity was enhanced by ivabradine, whereas exploratory behaviour was increased by melatonin and captopril. In conclusion, ivabradine, besides its potentially protective hemodynamic actions, does not seem to exert any disturbing effects on behaviour in L-NAME-induced hypertension in rats, while some of its effects were similar to captopril or melatonin. It is suggested that ivabradine used in cardiovascular indications is harmless regarding the effect on behaviour.


Subject(s)
Behavior, Animal/drug effects , Benzazepines/pharmacology , Captopril/pharmacology , Hypertension/drug therapy , Melatonin/pharmacology , NG-Nitroarginine Methyl Ester/metabolism , Angiotensin-Converting Enzyme Inhibitors/pharmacology , Animals , Antihypertensive Agents/pharmacology , Blood Pressure/drug effects , Heart Rate/drug effects , Hypertension/metabolism , Ivabradine , Locomotion/drug effects , Male , Nitric Oxide/metabolism , Nitric Oxide Synthase/metabolism , Rats , Rats, Wistar
4.
Eur Radiol ; 25(10): 2813-20, 2015 Oct.
Article in English | MEDLINE | ID: mdl-25813015

ABSTRACT

OBJECTIVE: Contrast-enhanced spectral mammography (CESM) examination results in a low-energy (LE) and contrast-enhanced image. The LE appears similar to a full-field digital mammogram (FFDM). Our aim was to evaluate LE CESM image quality by comparing it to FFDM using criteria defined by the European Reference Organization for Quality Assured Breast Screening and Diagnostic Services (EUREF). METHODS: A total of 147 cases with both FFDM and LE images were independently scored by two experienced radiologists using these (20) EUREF criteria. Contrast detail measurements were performed using a dedicated phantom. Differences in image quality scores, average glandular dose, and contrast detail measurements between LE and FFDM were tested for statistical significance. RESULTS: No significant differences in image quality scores were observed between LE and FFDM images for 17 out of 20 criteria. LE scored significantly lower on one criterion regarding the sharpness of the pectoral muscle (p < 0.001), and significantly better on two criteria on the visualization of micro-calcifications (p = 0.02 and p = 0.034). Dose and contrast detail measurements did not reveal any physical explanation for these observed differences. CONCLUSIONS: Low-energy CESM images are non-inferior to FFDM images. From this perspective FFDM can be omitted in patients with an indication for CESM. KEY POINTS: • Low-energy CESM images are non-inferior to FFDM images. • Micro-calcifications are significantly more visible on LE CESM than on FFDM. • There is no physical explanation for this improved visibility of micro-calcifications. • There is no need for an extra FFDM when CESM is indicated.


Subject(s)
Breast Neoplasms/diagnostic imaging , Mammography/standards , Aged , Breast/radiation effects , Calcinosis/diagnostic imaging , Early Detection of Cancer , Female , Humans , Mammography/methods , Middle Aged , Pectoralis Muscles/diagnostic imaging , Pectoralis Muscles/radiation effects , Phantoms, Imaging , Quality Control , Radiation Dosage , Radiographic Image Enhancement/methods , Random Allocation , Reference Standards , Retrospective Studies
5.
Pharmacol Biochem Behav ; 124: 284-9, 2014 Sep.
Article in English | MEDLINE | ID: mdl-24983779

ABSTRACT

OBJECTIVE: Doxorubicin is a recognized chemotherapeutic agent widely employed in human malignancies. The limiting factor of its use is a number of side effects. The aim of this work was to show, whether administration of doxorubicin could induce behavioral disturbances in rats, and whether angiotensin-converting enzyme inhibitor captopril or melatonin can modify these potential alterations. DESIGN AND METHODS: Four groups of 3-month-old Wistar rats (twelve per group) were treated for 4 weeks: control (placebo-treated), doxorubicin (DOX) (5mg/kg i.v. in a single intravenous dose), DOX rats treated with either melatonin (10mg/kg/24h) or captopril (100mg/kg/24h). Systolic blood pressure (SBP) and the level of oxidative stress were investigated and behavioral tests of anxiety-open field test (OF), elevated plus maze (EPM) and light-dark box (LDB) were accomplished. RESULTS: Doxorubicin increased significantly systolic blood pressure and parameters of oxidative stress. Moreover, doxorubicin enhanced the level of anxiety in the tests of OF, EPM, and LDB. Captopril and melatonin prevented the blood pressure rise and the enhancement of oxidative load. Importantly, both substances reduced the parameters of anxiety. CONCLUSION: Chronic administration of captopril or melatonin has shown anxiolytic effect in the model of doxorubicin-induced anxiety. It does not seem unreasonable to suppose that this protective effect of captopril or melatonin against anxiety development might have been related to the antioxidative effects of both substances.


Subject(s)
Antibiotics, Antineoplastic/pharmacology , Behavior, Animal/drug effects , Captopril/pharmacology , Doxorubicin/pharmacology , Melatonin/pharmacology , Animals , Biomarkers/metabolism , Blood Pressure/drug effects , Drug Antagonism , Male , Oxidative Stress/drug effects , Rats , Rats, Wistar
6.
Acta Physiol (Oxf) ; 210(4): 889-98, 2014 Apr.
Article in English | MEDLINE | ID: mdl-24410878

ABSTRACT

AIM: We aimed to investigate the histological and clinical presentations of experimental autoimmune myocarditis (EAM) induced by different immunization schemes. METHODS: Male young Lewis rats were divided into five groups immunized by porcine myocardial myosin: subcutaneously (SC) 2 mg (in two 1-mg doses on day 0 and 7), 0 mg (sham group) subcutaneously into rear footpads (RF), 0.25 mg RF, 0.5 mg RF or 1 mg RF (all RF once on day 0). On day 21, left ventricular (LV) function was assessed by cardiac magnetic resonance imaging and cardiac catheterization. The type and degree of myocardial inflammatory infiltrates were determined by conventional histology and immunohistochemistry. RESULTS: In the SC immunized rats and in the RF sham group, we observed 0% mortality, while in the actively RF immunized rats, mortality was 20, 20 and 44% for the 0.25 mg, 0.5 mg and 1 mg myosin doses respectively. Morbidity as defined by inflammatory infiltrates on haematoxylin and eosin (HE) staining was 22% in the SC immunized rats, 0% in the RF sham group and 100% in all actively RF immunized groups. We observed augmented relative ventricle weight and spleen weight, increased LV end-diastolic pressure, reduced LV developed pressure and reduced LV ejection fraction in all with myosin-immunized RF groups without any systematic dose effect. CONCLUSION: Subcutaneous immunization to the neck and flanks did not induce a reproducible EAM, while RF myosin administration reliably led to EAM. Lower myosin doses seem to induce the complete histological and clinical picture of EAM while being associated with lower mortality, non-specific symptoms and animal distress.


Subject(s)
Autoimmune Diseases , Myocarditis/immunology , Myosins/immunology , Animals , Immunization , Male , Myocardium/immunology , Myocardium/pathology , Myosins/administration & dosage , Random Allocation , Rats , Rats, Inbred Lew
7.
Physiol Res ; 62(Suppl 1): S135-41, 2013.
Article in English | MEDLINE | ID: mdl-24329693

ABSTRACT

Chronic continuous light exposure leads to melatonin deficiency along with complex neurohumoral activation resulting in hypertension development in rats. The aim of this study was to show, whether continuous light induces fibrotic rebuilding of the aorta and whether the treatment with melatonin or angiotensin converting enzyme inhibitor captopril can prevent these potential alterations. In a six-week experiment, 3-month-old Wistar rats were divided into 4 groups (ten per group): controls, rats exposed to continuous light, exposed to continuous light plus treated with captopril (100 mg/kg/24 h) and exposed to continuous light plus treated with melatonin (10 mg/kg/24 h). Systolic blood pressure (SBP) and collagen type I and III in the media of thoracic aorta were measured. Continuous light induced hypertension and fibrotic rebuilding of the aorta in terms of enhancement of collagen I and III concentration in the aortic media. Both captopril and melatonin prevented SBP rise and reduced collagen III concentration in the aorta. However, only melatonin reduced collagen I and the sum of collagen I and III in the aortic tissue. We conclude that in continuous light-induced hypertension, administration of melatonin, along with SBP reduction, decreases collagen I and III concentration in the aorta. It is suggested that antifibrotic effect of melatonin may reduce the stiffness of the aorta and small arteries and beneficially influence the nature of the pulse wave and peripheral vascular resistance.


Subject(s)
Aorta/physiopathology , Captopril/administration & dosage , Hypertension/etiology , Hypertension/physiopathology , Melatonin/administration & dosage , Photic Stimulation/adverse effects , Vascular Stiffness/drug effects , Animals , Antifibrinolytic Agents/administration & dosage , Antihypertensive Agents/administration & dosage , Aorta/drug effects , Fibrillar Collagens/metabolism , Hypertension/prevention & control , Light/adverse effects , Male , Rats , Rats, Wistar
8.
Physiol Res ; 62(Suppl 1): S181-9, 2013.
Article in English | MEDLINE | ID: mdl-24329698

ABSTRACT

Chronic kidney disease (CKD) represents a serious public health problem with increasing prevalence and novel approaches to renal protection are continuously under investigation. The aim of this study was to compare the effect of melatonin and angiotensin II type 2 receptor agonist compound 21 (C21) to angiotensin converting enzyme inhibitor captopril and angiotensin II type 1 receptor blocker olmesartan on animal model of doxorubicin nephrotoxicity. Six groups of 3-month-old male Wistar rats (12 per group) were treated for four weeks. The first group served as a control. The remaining groups were injected with a single dose of doxorubicin (5 mg/kg i.v.) at the same day as administration of either vehicle or captopril (100 mg/kg/day) or olmesartan (10 mg/kg/day) or melatonin (10 mg/kg/day) or C21 (0.3 mg/kg/day) was initiated. After four week treatment, the blood pressure and the level of oxidative stress were enhanced along with reduced glomerular density and increased glomerular size. Captopril, olmesartan and melatonin prevented the doxorubicin-induced increase in systolic blood pressure. All four substances significantly diminished the level of oxidative burden and prevented the reduction of glomerular density and modestly prevented the increase of glomerular size. We conclude that captopril, olmesartan, melatonin and C21 exerted a similar level of renoprotective effects in doxorubicin-induced nephrotoxicity.


Subject(s)
Captopril/therapeutic use , Imidazoles/therapeutic use , Melatonin/therapeutic use , Reactive Oxygen Species/metabolism , Receptor, Angiotensin, Type 2/agonists , Renal Insufficiency, Chronic/drug therapy , Renal Insufficiency, Chronic/physiopathology , Tetrazoles/therapeutic use , Angiotensin II Type 1 Receptor Blockers/therapeutic use , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Animals , Antioxidants/therapeutic use , Doxorubicin , Glomerular Filtration Rate/drug effects , Male , Oxidative Stress/drug effects , Rats , Rats, Wistar , Renal Agents/therapeutic use , Renal Insufficiency, Chronic/chemically induced , Treatment Outcome
9.
Bratisl Lek Listy ; 111(1): 54-6, 2010.
Article in English | MEDLINE | ID: mdl-20429314

ABSTRACT

Blood pressure measuring represents a routine investigation in general medicine. In the last decades large studies have determined average blood pressure values all around the world. Large clinical trials have shown that blood pressure reduction irrespective of the used type of therapeutic intervention reduces mortality. Based on the outcomes of these trials current guidelines for hypertension encourage more "aggressive" hypertension treatment compared to recommendations from the past. In clinical practice blood pressure is sometimes reduced even below normotensive values (at least in comparison with pre-treatment levels). However there is evidence that achieving too low levels of diastolic blood pressure during antihypertensive treatment has undesirable effects. Especially in the elderly a diastolic blood pressure reduction below 70 mm Hg should be avoided, because it is associated with increased mortality. A possible explanation of this phenomenon could be that antihypertensive treatment disequilibriates the balance between sufficient perfusion pressure and arteriolar vasodilation, both of which are required for adequate tissue perfusion. Impaired microcirculation, especially in the coronary bed may account for the increased mortality in hypertensive patients with low diastolic blood pressure levels. Thus we support the idea of cautious blood pressure reduction in the elderly. Furthermore, we suggest, that monitoring the level of tissue perfusion in treated hypertensive patients might help to provide individually tailored therapy (Fig. 1, Ref. 9). Full Text (Free, PDF) www.bmj.sk.


Subject(s)
Antihypertensive Agents/therapeutic use , Blood Pressure , Hypertension/physiopathology , Aged , Blood Pressure Determination , Diastole , Humans , Hypertension/drug therapy , Microcirculation
10.
Eur J Intern Med ; 20(2): 226-30, 2009 Mar.
Article in English | MEDLINE | ID: mdl-19327617

ABSTRACT

The authors aim to offer a holistic view on hypertension and its treatment. Their approach is fairly confrontational, particularly by suggesting that hypertension may play a role in optimizing the blood flow and enhancing oxygen delivery. An increase in blood pressure brings about a threat of catastrophes. Therefore hypertension might be considered as either a subsequent complication, or an inevitable adaptation. When changes of many complicated and complex mechanisms result in retention of sodium and water, then the treatment of this condition is so far the most logical conclusion, and possibly beneficial to the patient. This can be done by influencing the peripheral resistance or the load of vascular bed. However, in some cases a moderate overfilling of the system with no increase in heart rate could be interpreted as an optimal solution for organism that does not necessarily need to be medically treated. This may apply especially to young hypertensive patients, and in cases when no catastrophe is assumed to take place. Lowering the blood pressure to average population levels in each case, especially by means of aggressive therapy may not necessarily lead to improved tissue perfusion. A decrease in blood pressure reduces the risk of catastrophes. However, on the other hand, it can deteriorate the tissue perfusion and cause unfavorable long-term consequences.


Subject(s)
Adaptation, Physiological/physiology , Blood Pressure/physiology , Hypertension/physiopathology , Hypertension/therapy , Holistic Health , Humans
11.
Physiol Res ; 58(6): 793-798, 2009.
Article in English | MEDLINE | ID: mdl-19093737

ABSTRACT

Alterations of calcium handling and other second messenger cascades including protein kinase C (PKC) and A (PKA) were suggested to be responsible for abnormal vascular function in spontaneously hypertensive rats (SHR). However, the relative contribution of these pathways to vasoconstriction is still not completely understood. We investigated the effect of Ro 31-8220 (PKC inhibitor) and H89 (PKA inhibitor) on vasoconstriction induced by 120 mM KCl or by addition of 10 microM noradrenaline (NA) in isolated femoral arteries of control Wistar rats and SHR. Moreover, we investigated these responses in the presence and absence of Ca(2+) ions in the incubation medium in order to assess the role of calcium influx in these contractions. We observed that while the vasoconstriction in the presence of calcium was not different between Wistar and SHR, the difference between constriction elicited by NA addition in the absence and presence of external calcium was larger in SHR. The inhibition of PKC had no effect on constrictions in SHR, but diminished constrictions in Wistar rats. PKA inhibition slightly enhanced constrictions in Wistar rats, but reduced them in the presence of calcium in SHR. We conclude that vasoconstriction elicited by adrenergic stimulation is more dependent on extracellular calcium influx in SHR compared to Wistar rats. Moreover, the activation of PKA contributes to this calcium-dependent vasoconstriction in SHR but not in Wistar. On the other hand, PKC activation seems to play a less important role in vasoconstriction in SHR than in Wistar rats.


Subject(s)
Calcium/metabolism , Cyclic AMP-Dependent Protein Kinases/antagonists & inhibitors , Femoral Artery/drug effects , Hypertension/enzymology , Indoles/pharmacology , Isoquinolines/pharmacology , Protein Kinase C/antagonists & inhibitors , Protein Kinase Inhibitors/pharmacology , Sulfonamides/pharmacology , Vasoconstriction/drug effects , Animals , Cyclic AMP-Dependent Protein Kinases/metabolism , Disease Models, Animal , Femoral Artery/enzymology , Femoral Artery/physiopathology , Hypertension/physiopathology , In Vitro Techniques , Male , Norepinephrine/pharmacology , Potassium Chloride/pharmacology , Protein Kinase C/metabolism , Rats , Rats, Inbred SHR , Rats, Wistar , Vasoconstrictor Agents/pharmacology
12.
Acta Physiol (Oxf) ; 194(1): 45-55, 2008 Sep.
Article in English | MEDLINE | ID: mdl-18419778

ABSTRACT

AIM: We investigated, whether the substrate for nitric oxide (NO) formation -L-arginine - and the aldosterone receptor antagonist - spironolactone - are able to reverse alterations of the left ventricle (LV) and aorta in N(omega)-nitro-L-arginine methyl ester (L-NAME)-induced hypertension. METHODS: Six groups of male adult Wistar rats were investigated: controls after 4 and 7 weeks of experiment, rats treated with L-NAME for 4 weeks and three recovery groups: spontaneous-reversion (4 weeks L-NAME + 3 weeks placebo), spironolactone-induced reversion (4 weeks L-NAME + 3 weeks spironolactone) and L-arginine-induced reversion (4 weeks L-NAME+ 3 weeks L-arginine). Blood pressure was measured by tail-cuff plethysmography. Relative weight of the LV, myocardial fibrosis (based upon histomorphometry and hydroxyproline determination) and conjugated dienes in the LV and aortic cross-sectional area, inner diameter and wall thickness were determined. NO-synthase activity was investigated in the LV and aorta. RESULTS: L-NAME administration induced hypertension, left ventricular hypertrophy (LVH), LV fibrosis, aortic thickening and diminution of NO-synthase activity in the LV and aorta. Reduction in blood pressure and regression of LVH were observed in all recovery groups, yet reduction in LV fibrosis and aortic thickening were not. NO-synthase activity was restored only in the L-arginine and spironolactone group. CONCLUSION: In our study, the reversion of hypertension and LVH was not dependent on the restoration of NO-synthase activity. Moreover, LV fibrosis and aortic remodelling seem to be more resistant to conditions resulting in regression of LVH. Preserved level of fibrosis in the initial period of LVH regression might result in loss of structural homogeneity and possible functional alterations of the LV.


Subject(s)
Arginine/therapeutic use , Hypertension/drug therapy , Hypertrophy, Left Ventricular/drug therapy , Mineralocorticoid Receptor Antagonists , Nitric Oxide/deficiency , Spironolactone/therapeutic use , Animals , Aorta/pathology , Fibrosis , Hypertension/metabolism , Hypertension/pathology , Hypertrophy, Left Ventricular/metabolism , Male , Models, Animal , Myocardium/metabolism , NG-Nitroarginine Methyl Ester , Nitric Oxide Synthase/analysis , Nitric Oxide Synthase/metabolism , Rats , Rats, Wistar
13.
Cas Lek Cesk ; 147(1): 14-24, 2008.
Article in Slovak | MEDLINE | ID: mdl-18323038

ABSTRACT

Diagnosis of essential hypertension is created per exclusionem--with exclusion of all, so called secondary hypertensions (nephrogenic, endocrine conditioned etc). Idea and the name-essential hypertension are unclear. We have a lot of hypotheses about mechanisms of hypertension but no one is explaining satisfactorily the "fixation" of hypertension. From this point of view essential hypertension looks more like a syndrome than disease sui generis. Authors analyzed all possible pathways of hypertension origin as well as compensatory mechanisms in peripheral circulation in effort to reach relevant tissue perfusion. If these mechanisms lead to salt and water retention the best mode of the treatment would be to influence volume and blood vessels lumen. It is clear that optimization of blood pressure is advantageous for prevention of vascular catastrophes (myocardial and cerebral infarction). Nevertheless inadequate lowering of the peripheral tissue perfusion (kidney, CNS) can lead to degenerative changes in tissues and to disturbances in centrally regulated processes of blood pressure.


Subject(s)
Hypertension/physiopathology , Hemodynamics , Homeostasis , Humans , Water-Electrolyte Balance
14.
Physiol Res ; 56 Suppl 2: S71-S76, 2007.
Article in English | MEDLINE | ID: mdl-17824804

ABSTRACT

Although exposure to continuous light is associated with hypertension and modulates the outcome of ischemia-reperfusion injury, less attention has been paid to its effects on cardiac morphology. We investigated whether 4-week exposure of experimental rats to continuous 24 h/day light can modify cardiac morphology, with focus on heart weight, fibrosis and collagen I/III ratio in correlation with NO-synthase expression. Two groups of male adult Wistar rats were studied: controls exposed to normal light/dark cycle (12 h/day light, 12 h/day dark) and rats exposed to continuous light. After 4 weeks of treatment the absolute and the relative heart weights were determined and myocardial fibrosis and collagen type I/III ratio were evaluated using picrosirius red staining. Endothelial and inducible NO-synthase expression was detected immunohistochemically. The exposure of rats to continuous light resulted in an increase of body weight with proportionally increased heart weight. Myocardial fibrosis remained unaffected but collagen I/III ratio increased. Neither endothelial nor inducible NO-synthase expression was altered in light-exposed rats. We conclude that the loss of structural homogeneity of the myocardium in favor of collagen type I might increase myocardial stiffness and contribute to functional alterations after continuous light exposure.


Subject(s)
Light , Myocytes, Cardiac/radiation effects , Nitric Oxide Synthase Type II/metabolism , Animals , Body Weight/radiation effects , Collagen Type I/metabolism , Collagen Type III/metabolism , Fibrosis , Male , Myocytes, Cardiac/enzymology , Myocytes, Cardiac/pathology , Nitric Oxide Synthase Type III , Organ Size/radiation effects , Rats , Rats, Wistar , Time Factors
15.
Physiol Res ; 56 Suppl 2: S63-S69, 2007.
Article in English | MEDLINE | ID: mdl-17824805

ABSTRACT

Factors modulating cardiac susceptibility to ischemia-reperfusion (I/R) are permanently attracting the attention of experimental cardiology research. We investigated, whether continuous 24 h/day light exposure of rats can modify cardiac response to I/R, NO-synthase (NOS) activity and the level of oxidative load represented by conjugated dienes (CD) concentration. Two groups of male adult Wistar rats were studied: controls exposed to normal light/dark cycle (12 h/day light, 12 h/day dark) and rats exposed to continuous light for 4 weeks. Perfused isolated hearts (Langendorff technique) were exposed to 25 min global ischemia and subsequent 30 min reperfusion. The recovery of functional parameters (coronary flow, left ventricular developed pressure, contractility and relaxation index) during reperfusion as well as the incidence, severity and duration of arrhythmias during first 10 min of reperfusion were determined. The hearts from rats exposed to continuous light showed more rapid recovery of functional parameters but higher incidence, duration and severity of reperfusion arrhythmias compared to controls. In the left ventricle, the NOS activity was attenuated, but the CD concentration was not significantly changed. We conclude that the exposure of rats to continuous light modified cardiac response to I/R. This effect could be at least partially mediated by attenuated NO production.


Subject(s)
Light , Myocytes, Cardiac/radiation effects , Nitric Oxide Synthase/metabolism , Oxidative Stress/radiation effects , Reperfusion Injury/metabolism , Animals , Arrhythmias, Cardiac/metabolism , Arrhythmias, Cardiac/physiopathology , Body Weight/radiation effects , Coronary Circulation/radiation effects , Down-Regulation , Male , Myocardial Contraction/radiation effects , Myocytes, Cardiac/enzymology , Myocytes, Cardiac/pathology , Nitric Oxide/metabolism , Organ Size/radiation effects , Periodicity , Rats , Rats, Wistar , Reperfusion Injury/pathology , Reperfusion Injury/physiopathology , Time Factors , Ventricular Function, Left/radiation effects , Ventricular Pressure/radiation effects
16.
Physiol Res ; 56 Suppl 2: S55-S62, 2007.
Article in English | MEDLINE | ID: mdl-17824806

ABSTRACT

N(G)-nitro-L-arginine-methyl ester (L-NAME)-induced hypertension is associated with protein remodeling of the left ventricle. The aim of the study was to show, whether aldosterone receptor blocker spironolactone and precursor of NO-production L-arginine were able to reverse the protein rebuilding of the left ventricle. Six groups of male Wistar rats were investigated: control 4 (4 weeks placebo), L-NAME (4 weeks L-NAME), spontaneous-regression (4 weeks L-NAME + 3 weeks placebo), spironolactone-regression (4 weeks L-NAME + 3 weeks spironolactone), L-arginine-regression (4 weeks L-NAME + 3 weeks arginine), control 7 (7 weeks placebo). L-NAME administration induced hypertension, hypertrophy of the left ventricle (LV), and the increase of metabolic and contractile as well as soluble and insoluble collagenous protein concentration. The systolic blood pressure and relative weight of the LV decreased in all three groups with regression, while the most prominent attenuation of the LVH was observed after spironolactone treatment. In the spontaneous-regression and L-arginine-regression groups the concentrations of individual proteins were not significantly different from the control value. However, in the spironolactone-regression group the concentration of metabolic, contractile and insoluble collagenous proteins remained significantly increased in comparison with the control group. The persistence of the increased protein concentration in the spironolactone group may be related to the more prominent reduction of myocardial water content by spironolactone.


Subject(s)
Arginine/pharmacology , Hypertension/drug therapy , Hypertrophy, Left Ventricular/drug therapy , Mineralocorticoid Receptor Antagonists/pharmacology , Myocardium/metabolism , Spironolactone/pharmacology , Ventricular Remodeling/drug effects , Animals , Arginine/therapeutic use , Blood Pressure/drug effects , Collagen/metabolism , Hypertension/chemically induced , Hypertension/complications , Hypertension/metabolism , Hypertension/physiopathology , Hypertrophy, Left Ventricular/etiology , Hypertrophy, Left Ventricular/metabolism , Hypertrophy, Left Ventricular/physiopathology , Male , Mineralocorticoid Receptor Antagonists/therapeutic use , Muscle Proteins/metabolism , Myocardium/pathology , NG-Nitroarginine Methyl Ester , Nitric Oxide/metabolism , Organ Size/drug effects , Rats , Rats, Wistar , Remission, Spontaneous , Spironolactone/therapeutic use
17.
Physiol Res ; 56 Suppl 2: S25-S32, 2007.
Article in English | MEDLINE | ID: mdl-17824810

ABSTRACT

Aldosterone receptor antagonist, spironolactone, has been shown to prevent remodeling of the heart in several models of left ventricular hypertrophy. The aim of the present study was to determine whether the treatment with spironolactone can prevent hypertension, reduction of tissue nitric oxide synthase activity and left ventricular (LV) and aortic remodeling in N(G)-nitro-L-arginine methyl ester (L-NAME)-induced hypertension. Four groups of rats were investigated: control, spironolactone (200 mg/kg), L-NAME (40 mg/kg) and L-NAME + spironolactone (in corresponding dosage). Animals were studied after 5 weeks of treatment. The decrease of NO-synthase activity in the LV and kidney was associated with the development of hypertension and LV hypertrophy, with increased DNA concentration in the LV, and remodeling of the aorta in the L-NAME group. Spironolactone prevented the inhibition of NO-synthase activity in the LV and kidney and partially attenuated hypertension and LVH development and the increase in DNA concentration. However, remodeling of the aorta was not prevented by spironolactone treatment. We conclude that the aldosterone receptor antagonist spironolactone improved nitric oxide production and partially prevented hypertension and LVH development without preventing hypertrophy of the aorta in NO-deficient hypertension. The reactive growth of the heart and aorta seems to be controlled by different mechanisms in L-NAME-induced hypertension.


Subject(s)
Antihypertensive Agents/pharmacology , Aorta/drug effects , Hypertension/drug therapy , Hypertrophy, Left Ventricular/drug therapy , Mineralocorticoid Receptor Antagonists/pharmacology , Spironolactone/pharmacology , Ventricular Remodeling/drug effects , Animals , Antihypertensive Agents/therapeutic use , Aorta/pathology , Aorta/physiopathology , Blood Pressure/drug effects , Cell Proliferation/drug effects , DNA Replication/drug effects , Heart Ventricles/drug effects , Heart Ventricles/enzymology , Hypertension/chemically induced , Hypertension/complications , Hypertension/metabolism , Hypertension/pathology , Hypertension/physiopathology , Hypertrophy, Left Ventricular/etiology , Hypertrophy, Left Ventricular/metabolism , Hypertrophy, Left Ventricular/pathology , Hypertrophy, Left Ventricular/physiopathology , Kidney/drug effects , Kidney/enzymology , Male , Mineralocorticoid Receptor Antagonists/therapeutic use , NG-Nitroarginine Methyl Ester , Nitric Oxide/metabolism , Nitric Oxide Synthase/antagonists & inhibitors , Nitric Oxide Synthase/metabolism , Rats , Rats, Wistar , Spironolactone/therapeutic use , Time Factors
18.
Acta Physiol (Oxf) ; 191(4): 255-66, 2007 Dec.
Article in English | MEDLINE | ID: mdl-17680837

ABSTRACT

AIM: The relationship between increased sympathetic tone and enhanced activity of L-type voltage-dependent Ca2+ channels (L-VDCC) in spontaneously hypertensive rats (SHR) was studied using in vivo and in vitro approaches. METHODS: The effects of acute L-VDCC blockade on sympathetic vasoconstriction or blood pressure (BP) and the contribution of calcium influx to norepinephrine (NE)-induced arterial contraction were investigated in 10-week-old SHR and in age-matched SHR made normotensive by chronic captopril treatment from weaning. RESULTS: Blood pressure fall occurring after acute ganglionic or L-VDCC blockade was enhanced in SHR. Ganglionic blockade eliminated strain differences in BP response to acute L-VDCC blockade and vice versa, suggesting that enhanced contribution of L-VDCC is responsible for augmented sympathetic vasoconstriction in SHR. Both phasic (dependent on internal calcium stores) and tonic (dependent on calcium influx) contractions to NE were augmented in SHR femoral arteries in vitro. Nifedipine attenuated only tonic contractions but to a larger extent in SHR than in WKY arteries. Nifedipine effect was greater after endothelium removal, which augmented tonic but not phasic contractions after NE. Chronic captopril treatment of SHR prevented hypertension development by suppression of their sympathetic vasoconstriction including its nifedipine-sensitive component, but failed to influence enhanced NE-induced arterial contractions or increased relaxation to nifedipine in vitro. CONCLUSION: The contribution of nifedipine-sensitive component to noradrenergic vasoconstriction is enhanced during excessive NE stimulation (increased sympathetic tone of SHR in vivo or supramaximal NE stimulation in vitro). It seems that captopril-induced reduction of central sympathetic tone is able to normalize augmented nifedipine-sensitive vasoconstriction in SHR.


Subject(s)
Calcium Channels, L-Type/metabolism , Calcium/metabolism , Captopril/administration & dosage , Epinephrine/administration & dosage , Hypertension/metabolism , Ion Channel Gating/drug effects , Nifedipine/administration & dosage , Vasoconstriction/drug effects , Adrenergic Agonists/administration & dosage , Animals , Antihypertensive Agents/administration & dosage , Calcium Channel Blockers/administration & dosage , Dose-Response Relationship, Drug , Male , Rats , Rats, Inbred SHR
19.
Physiol Res ; 56(6): 671-684, 2007.
Article in English | MEDLINE | ID: mdl-18197748

ABSTRACT

The production of the pineal hormone melatonin is synchronized with day-night cycle via multisynaptic pathway including suprachiasmatic nucleus linking several physiological functions to diurnal cycle. The recent data indicate that impaired melatonin production is involved in several cardiovascular pathologies including hypertension and ischemic heart disease. However, the mechanisms of melatonin effect on cardiovascular system are still not completely understood. The activation of melatonin receptors on endothelial and vascular smooth muscle cells and antioxidant properties of melatonin could be responsible for the melatonin effects on vascular tone. However, the data from in vitro studies are controversial making the explanation of the melatonin effect on blood pressure in vivo difficult. In vivo, melatonin also attenuates sympathetic tone by direct activation of melatonin receptors, scavenging free radicals or increasing NO availability in the central nervous system. The central and peripheral antiadrenergic action of chronic melatonin treatment might eliminate the mechanisms counter-regulating decreased blood pressure, providing thus additional cardioprotective mechanism. The extraordinary antioxidant activity and antilipidemic effects of melatonin may enhance the modulation of blood pressure by melatonin and probably play the most important role in the amelioration of target organ damage by chronic melatonin treatment. Further investigation of these mechanisms should provide novel knowledge about pathophysiological mechanisms of cardiovascular diseases, additional explanation for their circadian and seasonal variability and potentially generate new impulses for the development of therapeutic arsenal.


Subject(s)
Antioxidants/pharmacology , Blood Pressure/drug effects , Cardiotonic Agents , Melatonin/pharmacology , Animals , Blood Vessels/drug effects , Blood Vessels/pathology , Humans , Hypertension/drug therapy , Hypertension/pathology
20.
Kidney Int ; 70(1): 170-6, 2006 Jul.
Article in English | MEDLINE | ID: mdl-16710350

ABSTRACT

Although angiotensin-converting enzyme (ACE) inhibitors are well-established drugs in the treatment of hypertension, they are not supposed to be sufficient in the inhibition of aldosterone formation. The present study analyzes the effect of aldosterone receptor antagonist, spironolactone and ACE inhibitor, captopril on nitric oxide (NO) and S-nitrosothiol formation in the kidney of N(G)-nitro-L-arginine methyl ester (L-NAME)-treated rats. Male Wistar rats were divided into six groups: (1) controls, (2) L-NAME (40 mg/kg/day), (3) spironolactone (200 mg/kg/day), (4) captopril (100 mg/kg/day), (5) L-NAME+spironolactone, and (6) L-NAME+captopril. After 4 weeks, NO synthase (NOS) activity, protein expression of endothelial NOS, inducible NOS and concentration of thiol and S-nitrosothiol groups were determined in the kidney. Besides the increase in systolic blood pressure (by 32%) and the decrease in NOS activity (by 37%), L-NAME treatment lowered the concentration of thiols (by 32%) and S-nitrosothiols (by 36%) in the renal tissue. Simultaneous treatment with spironolactone preserved NOS activity and S-nitrosothiols on the control level, whereas captopril did not affect these parameters modified by L-NAME treatment. Moreover, spironolactone increased expression of endothelial NOS protein without affecting inducible NOS protein expression. In conclusion, both captopril and spironolactone prevented L-NAME-induced hypertension and the decline of the antioxidant potential of the kidney tissue. However, only spironolactone improved NOS activity which led to the S-nitrosothiols formation. Both NO itself and S-nitrosothiols may contribute to the preventive effect of spironolactone against development of L-NAME-induced hypertension.


Subject(s)
Antihypertensive Agents/pharmacology , Hypertension, Renal/prevention & control , Kidney/drug effects , Mineralocorticoid Receptor Antagonists/pharmacology , Nitric Oxide/biosynthesis , S-Nitrosothiols/metabolism , Spironolactone/pharmacology , Angiotensin-Converting Enzyme Inhibitors/pharmacology , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Animals , Antihypertensive Agents/therapeutic use , Blood Pressure/drug effects , Captopril/pharmacology , Captopril/therapeutic use , Enzyme Inhibitors , Hypertension, Renal/chemically induced , Hypertension, Renal/enzymology , Kidney/chemistry , Kidney/metabolism , Male , Mineralocorticoid Receptor Antagonists/therapeutic use , NG-Nitroarginine Methyl Ester , Nitric Oxide/analysis , Nitric Oxide Synthase Type III/analysis , Nitric Oxide Synthase Type III/metabolism , Rats , Rats, Wistar , S-Nitrosothiols/analysis , Spironolactone/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...